Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease
靶向 BCL11A 的基因疗法可诱导胎儿血红蛋白并降低镰状细胞病患者的镰状血红蛋白
基本信息
- 批准号:9363943
- 负责人:
- 金额:$ 167.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-05 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:AdultAllogenicArchitectureAttenuatedAutologousBiologicalBloodCellsClinicalClinical TrialsDataDiseaseEngraftmentErythrocytesErythroidErythroid CellsFeasibility StudiesFetal HemoglobinFetal ReductionFutureGene ExpressionGene TransferGene-ModifiedGenesHalf-LifeHealthHematopoietic Stem Cell TransplantationHematopoietic stem cellsHemoglobinHemoglobinopathiesHumanIncidenceIndividualLaboratoriesLeadLifeMicroRNAsMolecularOutcomePatientsPhenotypeProtocols documentationPublishingRiskSeriesSeveritiesSiblingsSickle CellSickle Cell AnemiaSickle HemoglobinStem cellsToxic effectTransgenesTransplantationVirusbasebeta Thalassemiachronic graft versus host diseaseclinical effectcohortcurative treatmentscytotoxicitydisease phenotypefetalgamma Globingene therapygene transfer vectorgraft failuregraft vs host diseaseimprovedin vivoknock-downmathematical modelmortalitymouse modelmutantphase I trialpolymerizationpre-clinicalpreventsafety and feasibilitysicklingsmall hairpin RNAtargeted treatmentvector
项目摘要
Induction of fetal hemoglobin (HbF) in both sickle cell disease (SCD) and β-thalassemia is an extremely
promising approach to ameliorate the severity of both diseases. Recent molecular studies have revealed new
regulators of the fetal-to-adult hemoglobin switch in humans, including BCL11A. BCL11A is a genetically and
functionally validated regulator of γ-globin expression and a prime candidate for targeted therapy aimed at
induction of HbF in individuals with SCD. Curative treatment for SCD can be attained with hematopoietic stem
cell transplantation (HSCT). Graft failure and transplant-related mortality contribute to the significant
complications associated with allogeneic HSCT in SCD. Favorable outcomes in SCD are largely dependent on
the availability of matched sibling donors and the incidence of graft failure and graft versus host disease
(GVHD). Fewer than 10% of SCD patients have unaffected HLA-matched sibling potential donors. Gene
therapy for the hemoglobinopathies offers the clear advantage of eliminating the risk of GVHD and the need to
identify suitable stem cell donors by the use of autologous cells. Targeting BCL11A in SCD holds the significant
advantage that adequate knockdown of BCL11A in erythroid cells derived from gene-modified hematopoietic
stem cells (HSCs) will increase HbF expression while concurrently reducing expression of mutant HbS. Since
hemoglobin polymerization in sickle red cells is highly dependent on the intracellular concentration of HbS and
is strongly inhibited by HbF, vectors effectively targeting BCL11A should prevent the cellular phenotype of
sickle-containing red cells. Reduced hemoglobin polymerization would thus lead to a pronounced increase in
the red cell half-life in vivo. We have recently shown that that use of erythroid-specific expression of microRNA
adapted shRNAs (shRNAmiR) targeting BCL11A effectively induces HbF in human erythroid cells derived from
transduced HSCs, largely attenuating the hematologic effects of SCD in a murine model. Based on
mathematical modeling and preclinical data, we predict that transduction of human HSCs will reduce red cell
sickling in a range that will significantly attenuate the SCD phenotype. Based on these data, we propose a
pilot/feasibility study in a limited cohort of SCD patients determine the applicability of this approach.
在镰状细胞病(SCD)和β-地中海贫血中诱导胎儿血红蛋白(HbF)是一个非常重要的因素。
有希望的方法来改善这两种疾病的严重程度。最近的分子研究揭示了新的
人类胎儿到成人血红蛋白转换的调节因子,包括BCL 11 A。BCL 11 A是一种基因和
功能上经过验证的γ-珠蛋白表达调节剂,是靶向治疗的主要候选者,
SCD患者HbF诱导。造血干细胞移植是治疗SCD的有效方法
细胞移植(HSCT)。移植失败和移植相关的死亡率是导致
SCD中与同种异体HSCT相关的并发症SCD的有利结局主要取决于
匹配同胞供体的可用性以及移植物衰竭和移植物抗宿主病的发生率
(移植物抗宿主病)。少于10%的SCD患者有未受影响的HLA匹配的兄弟姐妹潜在供体。基因
血红蛋白病的治疗提供了消除GVHD风险的明显优势,
通过使用自体细胞鉴定合适的干细胞供体。在SCD中靶向BCL 11 A具有显著的
在源自基因修饰的造血干细胞的红系细胞中充分敲低BCL 11 A的优点
干细胞(HSC)将增加HbF表达,同时减少突变HbS的表达。以来
镰状红细胞中的血红蛋白聚合高度依赖于HbS的细胞内浓度,
被HbF强烈抑制,有效靶向BCL 11 A的载体应该防止BCL 11 A的细胞表型,
含镰状红细胞因此,血红蛋白聚合的减少将导致血红蛋白聚合的显著增加。
红细胞在体内的半衰期我们最近已经表明,使用红细胞特异性表达microRNA
靶向BCL 11 A的适应性shRNA(shRNAmiR)有效地诱导来自人红系细胞的HbF,
转导的HSC,在很大程度上减弱SCD在鼠模型中的血液学效应。基于
根据数学模型和临床前数据,我们预测人类HSC的转导将减少红细胞数量,
镰状化的范围将显著减弱SCD表型。基于这些数据,我们提出了一个
在有限的SCD患者队列中进行的试点/可行性研究确定了该方法的适用性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID A WILLIAMS其他文献
DAVID A WILLIAMS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID A WILLIAMS', 18)}}的其他基金
The role of Septin6 Group in Murine and Human Hematopoiesis
Septin6 组在小鼠和人类造血中的作用
- 批准号:
10718515 - 财政年份:2023
- 资助金额:
$ 167.34万 - 项目类别:
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease
靶向 BCL11A 的基因疗法可诱导胎儿血红蛋白并降低镰状细胞病患者的镰状血红蛋白
- 批准号:
10083551 - 财政年份:2020
- 资助金额:
$ 167.34万 - 项目类别:
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell Disease
靶向 BCL11A 的基因疗法可诱导胎儿血红蛋白并降低镰状细胞病患者的镰状血红蛋白
- 批准号:
10179447 - 财政年份:2017
- 资助金额:
$ 167.34万 - 项目类别:
Gene Therapy for SCID-X1 with Low Dose Busulfan and a SIN-lentiviral Vector
使用低剂量白消安和 SIN 慢病毒载体对 SCID-X1 进行基因治疗
- 批准号:
10827632 - 财政年份:2016
- 资助金额:
$ 167.34万 - 项目类别:
Development of novel selective Rac inhibitors for refractory leukemias
开发治疗难治性白血病的新型选择性 Rac 抑制剂
- 批准号:
9176356 - 财政年份:2016
- 资助金额:
$ 167.34万 - 项目类别:
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector
使用低剂量白消安和 SIN 慢病毒载体对 SCID-X1 进行基因治疗
- 批准号:
10207386 - 财政年份:2016
- 资助金额:
$ 167.34万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 167.34万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 167.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 167.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 167.34万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 167.34万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 167.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 167.34万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 167.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 167.34万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 167.34万 - 项目类别:
Grant-in-Aid for Scientific Research (B)